Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 596.5% in February

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) saw a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 11,249 shares, an increase of 596.5% from the January 29th total of 1,615 shares. Based on an average daily trading volume, of 11,160 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.2% of the shares of the company are sold short. Currently, 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 11,160 shares, the days-to-cover ratio is currently 1.0 days.

Alterity Therapeutics Stock Up 3.0%

Shares of ATHE stock traded up $0.10 during trading hours on Wednesday, reaching $3.43. The stock had a trading volume of 4,587 shares, compared to its average volume of 11,335. The firm has a 50-day simple moving average of $3.29 and a 200-day simple moving average of $3.94. Alterity Therapeutics has a twelve month low of $2.52 and a twelve month high of $7.00.

Analyst Upgrades and Downgrades

ATHE has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Wednesday, January 21st. Zacks Research upgraded Alterity Therapeutics to a “hold” rating in a research note on Thursday, February 12th. Finally, Canaccord Genuity Group assumed coverage on Alterity Therapeutics in a report on Wednesday, December 17th. They set a “speculative buy” rating for the company. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Institutional Investors Weigh In On Alterity Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Twin Lakes Capital Management LLC boosted its position in shares of Alterity Therapeutics by 2,250.3% during the third quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock worth $524,000 after buying an additional 133,333 shares during the period. HB Wealth Management LLC acquired a new stake in Alterity Therapeutics in the 3rd quarter valued at approximately $220,000. Greenleaf Trust raised its stake in Alterity Therapeutics by 88.2% during the 3rd quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock valued at $120,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in Alterity Therapeutics during the 3rd quarter valued at $83,000. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.